Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia

Published:2023-10-13 Issue:8 Volume:23 Page:4237-4248
ISSN:1591-9528
Container-title:Clinical and Experimental Medicine
language:en
Short-container-title:Clin Exp Med

Author:

Liu Xiangxing,Hu Binyi,Peng Nan,Chen Liming,Hu Dingyuan,Zhang Jiaojiao,Wang Lijue,Xie Zhenwei,Niu Suping,Lu Qian,Lu Jin,Fang Yi

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10238-023-01208-9.pdf

Reference23 articles.

1. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–60. https://doi.org/10.1182/blood-2017-09-806398.

2. Ahn IE, Farooqui M, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood. 2018;131(21):2357–66. https://doi.org/10.1182/blood-2017-12-820910.

3. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74. https://doi.org/10.1016/S0140-6736(10)61381-5.

4. Pal SS, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57. https://doi.org/10.1186/s12943-018-0779-z.

5. Garg N, Padron EJ, Rammohan KW, et al. Bruton's Tyrosine Kinase Inhibitors: the next frontier of b-cell-targeted therapies for cancer, autoimmune disorders, and multiple sclerosis. J Clin Med. 2022;11(20). https://doi.org/10.3390/jcm11206139

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction to: Evaluation of Bruton tyrosine kinase inhibitors monotherapy and combination therapy in lymphocytic leukemia;Clinical and Experimental Medicine;2023-12-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3